Online inquiry

IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7996MR)

This product GTTS-WQ7996MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7996MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2705MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ3527MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ13087MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ11715MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ7051MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ13920MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ1868MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ13610MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA R1450
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW